It seems they are giving out prizes for .. stuff I’ve already told you
..
Heh .. heh ..
http://tinyurl.com/bdhar
a)Chelating / binding of iron disallows it to rust / oxidize which
destroys
nitric oxide .. and by binding allows nitric oxide to be released
resulting in
increased vasular flow.
————————————————————————————————–
http://tinyurl.com/crxu9
Med Hypotheses 1998 Mar;50(3):239-51
A chelate theory for the mechanism of action of aspirin-like drugs.
Wang X
———————————————————————————————————-
New mechanism of action of Aspirin discovered
02 Oct 2005
Dr. Derek W. Gilroy from the Centre for Clinical Pharmacology and
Therapeutics in London is the winner of the 10th International
Aspirin® Award. The British scientist has unearthed a hitherto unknown
mechanism of action of acetylsalicylic acid (ASA) which explains how
the active ingredient of Aspirin® inhibits inflammation. Dr. Gilroy’s
research is unusual in that his studies into the anti-inflammatory mode
of action or, in other words, the inhibition of inflammation by ASA,
are completely novel. He has shown that the substance has the unique
ability to trigger the formation of nitric oxide. With the aid of this,
white blood cells are better able to fight infection.
"Dr. Gilroy has demonstrated a biological effect of ASA, providing
new insight into the mechanisms of action of acetylsalicylic acid in
terms of inflammation and congenital immunity," said Kurt Soland,
Head of the Region Europe in Bayer HealthCare’s Consumer Care Division,
in recognition of the Award Advisory Board’s decision. Added Soland,
"Dedicated young scientists like Dr. Gilroy are gradually eliciting
more and more of ASA’s secrets. The International Aspirin® Award
motivates them to study the substance and provides impetus for further
research."
Dr. Gilroy discovered in a series of experiments that ASA exerts its
full anti-inflammatory effect in acute inflammation through the
production of nitric oxide (NO). ASA was already known to inhibit the
formation within the body of prostaglandins or "pain amplifiers"
but that is not all that it does. The substance also produces
inflammation-inhibiting hormones known as lipoxins, which in turn form
nitric oxide (NO) and increase the nitric oxide levels in the blood.
This phenomenon plays a prominent role in particular in acute
inflammation, as NO regulates the transport of white blood cells to
sites of infection and injury. If ASA is taken, it is easier for white
blood cells to leave the blood system so that they can fight infection
or repair injuries to tissues. As a result, warmth, redness, swelling
and pain are reduced.
In his laudation to the British scientist, Professor Dr. Karsten
Schrör, Head of the Institute of Pharmacology and Clinical
Pharmacology at the Heinrich Heine University in Düsseldorf and a
member of the Aspirin® Award Scientific Advisory Board, again clearly
stressed the special significance of Dr. Gilroy’s experiments. "Dr.
Gilroy’s discovery considerably broadens the known spectrum of the
biological actions of the active ingredient of Aspirin® and
demonstrates that only some of the numerous biological activities of
ASA have been investigated to date."
About Bayer HealthCare AG
Bayer HealthCare AG, a subsidiary of Bayer AG, is one of the world’s
leading, innovative companies in the health care and medical products
industry. In 2004, the Bayer HealthCare subgroup generated sales
amounting to some EUR 8.5 billion.
The company combines the global activities of the divisions Animal
Health, Biological Products, Consumer Care, Diabetes Care, Diagnostics
and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide
in 2004.
Bayer HealthCare’s aim is to discover and manufacture innovative
products that will improve human and animal health worldwide. The
products enhance well-being and quality of life by diagnosing,
preventing and treating disease.
Forward-looking statements
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known
and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial
situation, development or performance of the company and the estimates
given here. These factors include those discussed in our public reports
filed with the Frankfurt Stock Exchange and with the U.S. Securities
and Exchange Commission (including our Form 20-F). The company assumes
no liability whatsoever to update these forward-looking statements or
to conform them to future events or developments.
http://www.press.bayer.com
——————————————————————————–
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore
DEAD PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking